Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A08700 | 32018285 | Dtsch Med Wochenschr | [Secondary causes of fatty liver disease - an update on pathogenesis, diagnosis and treatment strategies]. | 2020 | Details |
| A08701 | 32017891 | Am J Med | Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know? | 2020 | Details |
| A08702 | 32017849 | J Med Chem | [1,2,5]Oxadiazolo[3,4-b]pyrazine-5,6-diamine Derivatives as Mitochondrial Uncouplers for the Potential Treatment of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08704 | 32017389 | Diabetes Metab Res Rev | Lower eGFR is associated with increased probability of liver fibrosis in Chinese diabetic patients. | 2020 | Details |
| A08705 | 32017151 | J Food Biochem | Curcuma longa and Trigonella foenum graecum-enriched nutrient mixture from germinated Macrotyloma uniflorum and Vigna radiate ameliorate nonalcoholic fatty liver diseases in rats. | 2020 | Details |
| A08707 | 32016853 | Pharmacol Rep | New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis. | 2020 | Details |
| A08711 | 32015483 | Sci Rep | Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. | 2020 | Details |
| A08712 | 32015322 | Cell Death Dis | Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis. | 2020 | Details |
| A08713 | 32014594 | Int J Surg | Impact of sleeve gastrectomy and dietary change on metabolic and hepatic function in an obesity rat model - Experimental research. | 2020 | Details |
| A08714 | 32013841 | Curr Pharm Des | Lifestyle Changes for the Treatment of Nonalcoholic Fatty Liver Disease - A 2015-19 Update. | 2020 | Details |
| A08718 | 32012316 | Hepatology | Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A08729 | 32008345 | Orv Hetil | [Effects of physical activity in nonalcoholic fatty liver disease]. | 2020 | Details |
| A08731 | 32008185 | J Endocrinol Invest | Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD. | 2020 | Details |
| A08736 | 32006545 | Gastroenterology | AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. | 2020 | Details |
| A08738 | 32005637 | Ann Hepatol | Osteopontin - A potential biomarker of advanced liver disease. | 2020 | Details |
| A08744 | 32003662 | Curr Pharm Des | Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD). | 2020 | Details |
| A08748 | 32001554 | Gut | Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. | 2020 | Details |
| A08752 | 32000955 | J Am Coll Cardiol | Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. | 2020 | Details |
| A08761 | 31997561 | Liver Int | Collagen biology and non-invasive biomarkers of liver fibrosis. | 2020 | Details |
| A08766 | 31993196 | Ann Med Surg (Lond) | Work up of fatty liver by primary care physicians, review. | 2020 | Details |
| A08767 | 31992752 | Sci Rep | Biomarker discovery for chronic liver diseases by multi-omics - a preclinical case study. | 2020 | Details |
| A08769 | 31991487 | Hepatology | Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. | 2020 | Details |
| A08771 | 31991181 | Life Sci | Role of hepatic neuropeptide Y-Y1 receptors in a methionine-choline-deficient model of non-alcoholic steatohepatitis. | 2020 | Details |
| A08772 | 31990961 | PLoS One | Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis. | 2020 | Details |
| A08775 | 31988589 | World J Gastroenterol | Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma. | 2020 | Details |
| A08776 | 31987796 | Gastroenterology | Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A08783 | 31986085 | Annu Rev Med | Hiding in Plain Sight: Interleukin-11 Emerges as a Master Regulator of Fibrosis, Tissue Integrity, and Stromal Inflammation. | 2020 | Details |
| A08794 | 31982006 | Wiad Lek | The role of hydrogen sulfide in the progression of chronic obstructive pulmonary disease in patients with non-alcoholic steatohepatitis | 2019 | Details |
| A08799 | 31981449 | Clin Transl Sci | A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death. | 2020 | Details |
| A08802 | 31980251 | Trends Pharmacol Sci | Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08822 | 31978277 | Mol Nutr Food Res | Lipoatrophy-Associated Insulin Resistance and Hepatic Steatosis are Attenuated by Intake of Diet Rich in Omega 3 Fatty Acids. | 2020 | Details |
| A08825 | 31975453 | J Gastroenterol Hepatol | Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population. | 2020 | Details |
| A08839 | 31969775 | World J Gastroenterol | Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. | 2020 | Details |
| A08840 | 31969650 | Sci Rep | Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects. | 2020 | Details |
| A08845 | 31968655 | Nutrients | Decreased PEDF Promotes Hepatic Fatty Acid Uptake and Lipid Droplet Formation in the Pathogenesis of NAFLD. | 2020 | Details |
| A08847 | 31968197 | Endocr Pract | IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE. | 2020 | Details |
| A08848 | 31967400 | Liver Int | Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. | 2019 | Details |
| A08850 | 31966908 | World J Hepatol | Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. | 2019 | Details |
| A08853 | 31965669 | Liver Int | Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos. | 2020 | Details |
| A08854 | 31965579 | Hepatology | Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. | 2020 | Details |
| A08855 | 31965018 | Sci Rep | Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice. | 2020 | Details |
| A08866 | 31957704 | Eur Cytokine Netw | lncRNA NEAT1 regulates fibrosis and inflammatory response induced by nonalcoholic fatty liver by regulating miR-506/GLI3. | 2019 | Details |
| A08867 | 31956961 | Diabetes Ther | Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A08871 | 31955626 | Endocr Res | Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice. | 2020 | Details |
| A08872 | 31955491 | Diabetes Metab Res Rev | Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. | 2020 | Details |
| A08873 | 31955065 | Int Immunopharmacol | Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice. | 2020 | Details |
| A08874 | 31954687 | Lancet Gastroenterol Hepatol | Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study. | 2020 | Details |
| A08880 | 31953745 | Obes Surg | Fibroscan-Based Score to Predict Significant Liver Fibrosis in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A08883 | 31953228 | Biochim Biophys Acta Mol Cell Biol Lipids | Effects of peptidoglycan on the development of steatohepatitis. | 2020 | Details |
| A08890 | 31950811 | Acta Gastroenterol Belg | Impact of liver inflammation on whole body insulin resistance : a case report on primary biliary cholangitis. | 2020 | Details |
| A08893 | 31950520 | Hepatology | Nonphagocytic Activation of NOX2 Is Implicated in Progressive Nonalcoholic Steatohepatitis During Aging. | 2020 | Details |
| A08898 | 31949129 | Cell Death Dis | Targeting alkaline ceramidase 3 alleviates the severity of nonalcoholic steatohepatitis by reducing oxidative stress. | 2020 | Details |
| A08899 | 31948298 | Expert Opin Investig Drugs | Targeting the Wnt signaling pathway: the challenge of reducing scarring without affecting repair. | 2020 | Details |
| A08900 | 31948295 | Expert Opin Investig Drugs | Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)? | 2020 | Details |
| A08905 | 31943293 | Hepatology | Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. | 2020 | Details |
| A08906 | 31943268 | Aliment Pharmacol Ther | Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check-up clinic population. | 2020 | Details |
| A08907 | 31942560 | Animal Model Exp Med | A simple method for inducing nonalcoholic steatohepatitis with fibrosis. | 2019 | Details |
| A08909 | 31941930 | Sci Rep | Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis. | 2020 | Details |
| A08914 | 31940395 | PLoS One | The diagnostic accuracy of liver fibrosis in non-viral liver diseases using acoustic radiation force impulse elastography: A systematic review and meta-analysis. | 2020 | Details |
| A08915 | 31940200 | J Med Chem | Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08918 | 31939698 | AJR Am J Roentgenol | Portal Venous Pulsatility Index: A Novel Biomarker for Diagnosis of High-Risk Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A08926 | 31935496 | J Ethnopharmacol | A review of Penthorum chinense Pursh for hepatoprotection: Traditional use, phytochemistry, pharmacology, toxicology and clinical trials. | 2020 | Details |
| A08930 | 31933238 | Pharmaceut Med | Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date. | 2019 | Details |
| A08931 | 31932588 | Nat Commun | SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. | 2020 | Details |
| A08933 | 31931543 | Z Gastroenterol | [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?] | 2020 | Details |
| A08936 | 31930920 | J Med Chem | The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. | 2020 | Details |
| A08938 | 31930835 | Pak J Biol Sci | FICK-3 Score Combining Fibrosis-4, Insulin Resistance and Cytokeratin-18 in Predicting Non-alcoholic Steatohepatitis in NAFLD Egyptian Patients. | 2019 | Details |
| A08950 | 31928239 | Expert Rev Gastroenterol Hepatol | Fatty liver in pregnancy: a narrative review of two distinct conditions. | 2020 | Details |
| A08952 | 31926994 | Eur J Pharmacol | Challenges and opportunities in drug development for nonalcoholic steatohepatitis. | 2020 | Details |
| A08957 | 31926204 | Metabolism | Epigenetic silencing of microRNA-125b-5p promotes liver fibrosis in nonalcoholic fatty liver disease via integrin α8-mediated activation of RhoA signaling pathway. | 2020 | Details |
| A08963 | 31923578 | Diabetes Metab | Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. | 2020 | Details |
| A08965 | 31922994 | Clin Transl Gastroenterol | A Human REPIN1 Gene Variant: Genetic Risk Factor for the Development of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A08966 | 31922976 | Eur J Gastroenterol Hepatol | Noninvasive assessment of liver fibrosis in a real-world cohort of patients with known or suspected chronic liver disease using 2D-shear wave elastography. | 2020 | Details |
| A08968 | 31921875 | Front Med (Lausanne) | PNPLA3-A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease. | 2019 | Details |
| A08973 | 31919793 | Pharmacoeconomics | Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. | 2020 | Details |
| A08975 | 31919231 | Gut | S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development. | 2020 | Details |
| A08989 | 31914044 | Medicine (Baltimore) | Urinary fatty acid and retinol binding protein-4 predict CKD progression in severe NAFLD patients with hypertension: 4-year study with clinical and experimental approaches. | 2020 | Details |
| A09000 | 31909356 | Hepatol Commun | Circulating MicroRNA-122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD. | 2019 | Details |
| A09003 | 31907981 | J Gastroenterol Hepatol | Liver stiffness measurement in non-alcoholic fatty liver disease: Two is better than one. | 2020 | Details |
| A09007 | 31906832 | Stroke | Liver Fibrosis Indices and Outcomes After Primary Intracerebral Hemorrhage. | 2020 | Details |
| A09011 | 31905026 | Am J Physiol Gastrointest Liver Physiol | Addition of trans fat and alcohol has divergent effects on atherogenic diet-induced liver injury in rodent models of steatohepatitis. | 2020 | Details |
| A09012 | 31905025 | Am J Physiol Gastrointest Liver Physiol | Investigating fibrosis and inflammation in an ex vivo NASH murine model. | 2020 | Details |
| A09015 | 31903720 | Liver Int | Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation. | 2020 | Details |
| A09019 | 31902937 | Biol Pharm Bull | Repeated Administration of Kupffer Cells-Targeting Nanoantioxidant Ameliorates Liver Fibrosis in an Experimental Mouse Model. | 2020 | Details |
| A09026 | 31899984 | Expert Opin Investig Drugs | Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis. | 2020 | Details |
| A09033 | 31897838 | Eur J Pediatr | Causes of secondary non-alcoholic fatty liver disease in non-obese children below 10 years. | 2020 | Details |
| A09034 | 31897769 | Acta Diabetol | Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. | 2020 | Details |
| A09035 | 31896166 | J Gastroenterol Hepatol | Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases. | 2020 | Details |
| A09044 | 31891606 | PLoS One | Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH). | 2019 | Details |
| A09048 | 31889753 | J Clin Exp Hepatol | Childhood and Adolescent Nonalcoholic Fatty Liver Disease: Is It Different from Adults? | 2019 | Details |
| A09049 | 31889539 | Transplant Proc | Minimally Invasive Sleeve Gastrectomy as a Surgical Treatment for Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients. | 2019 | Details |
| A09056 | 31888083 | Int J Mol Sci | Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules. | 2019 | Details |
| A09057 | 34350368 | Cardiol Plus | Bile Acid and Cholesterol Metabolism in Atherosclerotic Cardiovascular Disease and Therapy. | 2020 | Details |
| A09061 | 31887811 | Gut Liver | Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index. | 2020 | Details |
| A09062 | 31887451 | Clin Gastroenterol Hepatol | High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09063 | 31887443 | Clin Gastroenterol Hepatol | Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. | 2019 | Details |
| A09065 | 31887369 | J Hepatol | A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. | 2019 | Details |
| A09068 | 31885733 | Dis Markers | Optimizing the Use of the Gamma-Glutamyl Transpeptidase-to-Platelet Ratio and Transient Elastography to Identify Liver Cirrhosis in Patients with Chronic Hepatitis B Concurrent with Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09074 | 31883514 | BMC Gastroenterol | Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. | 2019 | Details |
| A09075 | 31883410 | Liver Int | Hepatitis B virus activity is not associated with degree of liver steatosis in patients with hepatitis B-related chronic liver disease. | 2020 | Details |